Recruiting Neuromyelitis Optica Studies in Boston
Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder
A Phase 2, open-label, multicenter study to evaluate the pharmacokinetics (PK), pharmacodynamics (PD), and safety of inebilizumab in eligible pediatric participants 2 to \< 18 years of age with recent...
Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD
The primary purpose of this study is to evaluate the safety and efficacy of ravulizumab in pediatric participants with Neuromyelitis Optica Spectrum Disorder (NMOSD)....
About Neuromyelitis Optica Clinical Trials in Boston
Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune disease that primarily attacks the optic nerves and spinal cord, causing vision loss and paralysis. It is distinct from multiple sclerosis and often involves aquaporin-4 antibodies. Treatment includes immunosuppressive therapies and biologics.
There are currently 2 neuromyelitis optica clinical trials recruiting participants in Boston, MASSACHUSETTS. These studies are seeking a combined 27 participants. Research is being sponsored by Amgen, Alexion Pharmaceuticals, Inc.. Clinical trial participation is free and participants receive study-related medical care at no cost.
Neuromyelitis Optica Clinical Trials in Boston — FAQ
Are there neuromyelitis optica clinical trials in Boston?
Yes, there are 2 neuromyelitis optica clinical trials currently recruiting in Boston, MASSACHUSETTS. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Boston?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Boston research site will contact you about next steps.
Are clinical trials in Boston free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Boston studies also compensate for your time and travel.
What neuromyelitis optica treatments are being tested?
The 2 active trials in Boston are testing new therapies including novel drugs, biologics, and treatment approaches for neuromyelitis optica.
Data updated March 2, 2026 from ClinicalTrials.gov